PA
ALXN

Pinnacle Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Pinnacle Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,429
Closed -$1.14M – 781
2021
Q1 		$1.14M Sell
7,429
-1,100
-13% -$170K 0.02% 399
2020
Q4 		$1.33M Sell
8,529
-685
-7% -$88K 0.03% 362
2020
Q3 		$1.05M Buy
9,214
+200
+2% +$21.6K 0.03% 360
2020
Q2 		$1.01M Sell
9,014
-9,165
-50% -$973K 0.03% 361
2020
Q1 		$1.63M Sell
18,179
-1,256
-6% -$123K 0.05% 278
2019
Q4 		$2.1M Buy
19,435
+60
+0.3% +$6.42K 0.05% 300
2019
Q3 		$1.9M Buy
19,375
+5,175
+36% +$583K 0.04% 314
2019
Q2 		$1.86M Buy
14,200
+550
+4% +$70.9K 0.04% 316
2019
Q1 		$1.84M Buy
13,650
+2,050
+18% +$255K 0.04% 313
2018
Q4 		$1.13M Buy
11,600
+1,500
+15% +$177K 0.03% 376
2018
Q3 		$1.4M Buy
+10,100
New +$1.27M 0.03% 363

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Pinnacle Associates's ALXN Position: Q2 2021 in Review

Pinnacle Associates sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 7,429 shares — an estimated $1.14M sold.

Pinnacle Associates first reported a position in ALXN in Q3 2018 and held it in 11 quarters. The position peaked at $2.1M in Q4 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Pinnacle Associates reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Pinnacle Associates sold 7,429 Alexion Pharmaceuticals shares in Q2 2021, an estimated $1.14M.
  • Pinnacle Associates first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 11 quarters.
  • Pinnacle Associates's Alexion Pharmaceuticals position peaked at $2.1M in Q4 2019.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Pinnacle Associates's 13F filing for Q2 2021, filed 2 Aug 2021.